Eusa Pharma acquires iMCD treatment Sylvant for $115m

This article was originally published here

Sylvant secured approval in over 40 countries to treat idiopathic multicentric Castleman’s disease (iMCD), which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma,

The post Eusa Pharma acquires iMCD treatment Sylvant for $115m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply